# **Key Information Document**

# Beyond Alterosa A sub-fund of DNCA Invest SICAV



Share class: I (EUR) - ISIN: LU1907594664

# **Purpose**

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

#### **Product**

Product name: Beyond Alterosa

Beyond Alterosa is a sub-fund of DNCA Invest SICAV regulated by Luxembourg

Law.

Name of the manufacturer: DNCA Finance ISIN: DNCA Finance LU1907594664

Manufacturer's website: www.dnca-investments.com

Phone: For further information call +33158625500

This Product is managed by DNCA Finance, authorized in France under n°GP00030 and regulated by the Autorité des marchés financiers.

This Product is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier.

 $Further information is available on the {\it Management Company's website:} www.dnca-investments.com.$ 

Key Information Document production date: 05/08/2024.

# What is this product?

#### **TYPE**

This Product is a sub-fund of DNCA Invest SICAV, an investment company with variable capital regulated by Luxembourg law and qualifying as UCITS pursuant to Directive 2009/65/CE.

#### **TERM**

The Product is established for an unlimited duration and liquidation must be decided upon by the Board of Directors.

#### **OBJECTIVES**

The Product seeks to outperform the 30% MSCI World All Countries World Net Return + 70% Bloomberg Barclays Pan European Corporate Euro Hedged Index. calculated with dividends reinvested, over the recommended period. Investors' attention is drawn to the fact that the management style is discretionary and integrates environmental, social/societal and governance (ESG) criteria.

The Product is managed taking into consideration Responsible and Sustainable principles and has as its objective sustainable investment within the meaning of Article 9 of SFDR. The Product is managed taking into consideration responsible and sustainable principles and aims to be target issuers with a significatively exposure of percentage or their revenues to the 17 Sustainable Development Goals of the United Nations. The investment process take into account internal scoring based on an extra-financial analysis through a proprietary rating model (ABA, Above & Beyond Analysis) developed internally by DNCA. The risk exists that the models used to make these investment decisions do not perform the tasks they were designed to. The use of the proprietary tool relies on the experience, relationships and expertise of DNCA with the "best in universe" method. There may be a sector bias. The Product will proceed to the extra-financial analysis on at least 90% of its securities, while excluding 20% of the worst issuers from its investment universe. Additional information on SRI strategy may be obtained in the prospectus of the Product. Through active management of a portfolio of Euro denominated equities and fixed income products, it aims to provide an alternative to investments in bonds and convertible bonds (directly or through mutual funds) as well as an alternative to Euro denominated funds. The Product however does not benefit from a guarantee on capital invested. The investment process is based on the following three stages: (i) exclusion of companies with high corporate responsibility risks, (ii) selection of issuers and companies identified to meet the Product's sustainable strategy and (iii) build the portfolio pursuant to a fundamental analysis, the liquidity and the valuation of the companies considered.

The Product may invest at any time within the following limits in:

- up to 100% of its net assets may be exposed to fixed income securities denominated in Euro or in other currency, composed of securities issued by public or private sector-issuers, investment grade rated;
- up to 50% of its net assets may be composed of fixed income securities belonging to the "speculative grade" (i.e. which have ratings below a Standard & Poor's minimum A-3 short term rating or BBB-long-term rating or equivalent with a minimum of CCC) or non-rated.

 $The \, Management \, Company \, shall \, not \, solely \, base \, its \, investment \, decisions \, on \, the \, ratings \, assigned \, by \, independent \, rating \, agencies, \, but \, shall \, also \, proceed \, to \, its \, own \, credit \, risk \, assessment.$ 

- up to 50% of its net assets in equities or equivalent from issuers belonging to all market capitalisation categories, headquartered in OECD countries:
- Investment in equities or equivalent issued by issuers which capitalisation is under 200 million Euros may not exceed 5% of the net asset of the Sub-Fund:
- up to 100% of its net assets in securities outside of OECD countries;
- up to 100% of its net assets in securities denominated in other currency than Euro;
- up to 50% of this net assets in convertibles or exchangeable bonds and up to 20% of its total assets in contingent convertibles bonds;
- up to 5% of its net assets may be invested in securities which may qualify as distressed securities (i.e. which have a Standard & Poor's notation below CCC long-term rating or equivalent).
- up to 15% of its net assets in assets backed securities (ABS) and mortgage backed securities (MBS) which shall consist of securities that
  are rated at least B- by Standard & Poor's for example or that are considered of a comparable credit quality by the Management
  Company.

The exchange rate risk will not exceed 100% of the net asset of the Product.

In case of adverse market conditions, the Product may invest up to 100% of its net asset in money market instruments.

The Product may invest up to 10% of its net assets in units and/or shares of UCITS and/or other UCIs, including ETFs.

In order to achieve the investment objective, the Product may also invest in all types of eligible derivatives instruments traded on regulated or OTC markets when these contracts are better suited to the management objective or offer lower trading costs. These instruments may include, but are not restricted to, futures, options, swaps, CDS on indices and CDS. Derivative instruments may be used for hedging purposes.

The Product is actively managed and uses the benchmark for performance comparison purposes. This means the Management Company is taking investment decisions with the intention of achieving the Product's investment objective; this may include decisions regarding asset selection and overall level of exposure to the market. The Management Company is not in any way constrained by the benchmark in its portfolio positioning. The deviation from the benchmark may be complete or significant.

This is an accumulation share.

#### **INTENDED RETAIL INVESTORS**

The Product is intended for retail investors who have no financial knowledge or experience of the financial sector. The Product is intended  $for investors \, who \, can \, with stand \, capital \, losses \, and \, who \, do \, not \, require \, a \, capital \, guarantee.$ 

#### OTHER INFORMATION

and you may get back less

The Depositary is BNP Paribas, Luxembourg Branch.

The full prospectus and lastest key information document, as well as lastest annual report are available on the website www.dnca-investments.com or directly from the manufacturer: DNCA Finance at 19 Place Vendôme 75001 Paris.

The NAV is available on the website: www.dnca-investments.com.

# What are the risks and what could I get in return?



Lowerrisk **Higher risk** The risk indicator assumes you keep the product for 3

The risk can be significantly different if you cash in at an early stage

The summary risk indicator is a guide to the level of risk of this Product compared to other products. It shows how likely it is that the Product will lose money because of movements in the markets or because we are not able to pay you. The essential risks of the Product lie in the possibility of depreciation of the securities in which the Product is invested.

We have classified this Product as 3 out of 7, which is a medium-low

This rates the potential losses from future performance at a medium-low level, and poor market conditions are unlikely to impact our capacity to pay you.

Other risks materially relevant to the Product and which could lead to a fall in the net asset value to which the indicator gives too little consideration: operational risk

This Product does not include any protection from future market performance, so you could lose some or all of your investment.

#### **PERFORMANCE SCENARIOS**

The figures shown include all the costs of the Product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back. What you will get from this Product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the Product and a suitable proxy over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances. What you get will depend on market trends and how the stress scenario shows what you might get back in extreme market circumstances. What you get will depend on market trends and how the stress scenario shows what you might get back in extreme market circumstances. What you get will depend on market trends and how the stress scenario shows what you might get back in extreme market circumstances. What you get will depend on market trends and how the stress scenario shows what you might get back in extreme market circumstances. What you get will depend on market trends and how the stress scenario shows a stress scenario shows the stress scenario shows thelong you keep the Product.

Recommended holding period:	3 years	
Example investment	EUR10 000	
	lfyou exit after 1 year	Ifyou exit after 3 years

#### **SCENARIOS**

Minimum	$There is no {\it minimum guaranteed return.} You {\it could lose some or all of your investment.}$			
Stress	What you might get back after costs Average return each year	EUR 8580 -14.2%	EUR 8100 -6.8%	
Unfavourable	What you might get back after costs Average return each year	EUR 8580 -14.2%	EUR 9180 -2.8%	
Moderate	What you might get back after costs Average return each year	EUR 10200 2.0%	EUR 10560 1.8%	
Favourable	What you might get back after costs Average return each year	EUR 11410 14.1%	EUR 11950 6.1%	

- The unfavourable scenario occurred for an investment in the Product between September 2019 and September 2022.
- The moderate scenario occurred for an investment in the proxy between June 2015 and June 2018.
- The favourable scenario occurred for an investment in the Product between December 2018 and December 2021.

# What happens if DNCA Finance is unable to pay out?

The Product is a co-ownership of financial instruments and deposits separate from DNCA Finance. In the event of the default of DNCA Finance, the assets of the Product held by the depositary will not be affected. In the event of default by the depositary, the risk of financial loss of the Product is mitigated due to the legal segregation of the depositary's assets from those of the Product.

### What are the costs?

The person advising on or selling you this Product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

#### **COSTS OVER TIME**

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the Product and how well the Product does.

The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the Product performs as shown in the moderate scenario.
- FUR 10 000 is invested.

#### Investment of EUR 10 000 If you exit after 1 year If you exit after 3 years

Total costs	EUR187	EUR 385
Annual cost impact (*)	1.9%	1.2% each year

 $<sup>^*</sup>$  The annual cost impact illustrates how costs reduce your return each year over the holding period. For example, it shows that if you exit at the recommended holding period your average return per year is projected to be 3.0% before costs and 1.8% after costs.

We may share part of costs with the person selling you the Product to cover the services they provide to you. These figures include the maximum distribution fee and which amount of 100% of costs. This person will inform you of the actual distribution fee.

#### **COMPOSITION OF COSTS**

One-off costs upon entry or exit		If you exit after 1 year			
Entry costs	Up to 1.00% of the amount you pay in when entering this Investment. This is the most you will be charged. The person selling you the Product will inform you of the actual charge.	Upto EUR100			
Exit costs	We do not charge an exit fee for this Product.	None			
Ongoing costs taken each year					
Management fees and other administrative or operating costs	0.81% of the value of your investment per year. This is an estimate based on actual costs over the last year.	EUR81			
Transaction costs	0.06% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the Product. The actual amount will vary depending on how much we buy and sell.	EUR6			
Incidental costs taken under specific conditions					
Performance fees	20.00% of the positive performance net of any fees above the 30% MSCI All Countries World Net Return + 70% Bloomberg Pan European Corporate Euro Hedged composite index, with High Water Mark. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years.	EUR0			

# How long should I hold it and can I take my money out early?

#### Recommended holding period: 3 years.

Shareholders may redeem shares on demand and executed on each NAV calculation and publication day before 12.00 noon (Luxembourg time).

 $The \, recommended \, holding \, period \, was \, chosen \, depending \, on \, the \, asset \, class, investment \, strategy \, and \, risk \, profile \, of \, the \, Product, to \, enable \, it \, to \, achieve \, its \, investment \, objective \, while \, minimizing \, the \, risk \, of \, loss.$ 

You can redeem all or part of your investment at any time before the end of the recommended holding period, or hold it longer. There are no penalties for early divestment. However, if you request redemption before the end of the recommended holding period, you may receive less than expected.

 $The \textit{Product} has a \textit{redemption} \textit{capping} \textit{system} \textit{know} \textit{as} \, \\ \textit{``Gates''} \textit{ described} \textit{ in the prospectus}.$ 

### How can I complain?

If you have any compliants about the Product, you can send a written request with a description of the problem either by e-mail dnca@dnca-investments.comortothefollowingaddress:DNCAFinance,19PlaceVendôme,75001Paris.

#### Other relevant information

The Product promotes environmental or social and governance (ESG) criteria within the meaning of Article 9 of Regulation (EU) 2019/2088 on sustainability reporting in the financial services sector ("SFDR Regulation").

The Product's prospectus and the latest key information document, as well as the latest annual report and information on past performance, can be obtained free of charge from the website of the manufacturer: www.dnca-investments.com.

When this Product is used as a unit-linked carrier in a life insurance or capitalization contract, additional information on this contract, such as the costs of the contract, which are not included in the costs indicated in this document, the contact in the event of a claim and what happens in the event of default by the insurance company, are presented in the key information document for this contract, which must be provided by your insurer or broker or any other insurance intermediary in accordance with its legal obligation.